Literature DB >> 2934067

Hypoxia-mediated nitro-heterocyclic drugs in the radio- and chemotherapy of cancer. An overview.

G E Adams, I J Stratford.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2934067     DOI： 10.1016/0006-2952(86)90560-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  12 in total

1.  Solubility behavior, phase transition, and structure-based nucleation inhibition of etanidazole in aqueous solutions.

Authors:  M B Maurin; S M Rowe; K S Field; R C Swintosky; M A Hussain
Journal:  Pharm Res       Date:  1996-09       Impact factor: 4.200

2.  Sensitization of C6 glioma to carboplatin cytotoxicity by hyperthermia and thymidine.

Authors:  J D Cohen; H I Robins; M J Javid
Journal:  J Neurooncol       Date:  1990-08       Impact factor: 4.130

3.  Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases.

Authors:  Jacobus F A Jansen; Heiko Schöder; Nancy Y Lee; Ya Wang; David G Pfister; Matthew G Fury; Hilda E Stambuk; John L Humm; Jason A Koutcher; Amita Shukla-Dave
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-11-10       Impact factor: 7.038

4.  Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.

Authors:  Nancy Y Lee; James G Mechalakos; Sadek Nehmeh; Zhixiong Lin; Olivia D Squire; Shangde Cai; Kelvin Chan; Pasquale B Zanzonico; Carlo Greco; Clifton C Ling; John L Humm; Heiko Schöder
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-14       Impact factor: 7.038

5.  Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine.

Authors:  D W Siemann
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

6.  Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?

Authors:  E C Chinje; A V Patterson; M P Saunders; S D Lockyer; A L Harris; I J Stratford
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

7.  Characterization of radiation resistant hypoxic cell subpopulations in KHT sarcomas. (II). Cell sorting.

Authors:  D W Siemann; P C Keng
Journal:  Br J Cancer       Date:  1988-09       Impact factor: 7.640

8.  Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).

Authors:  A V Patterson; H M Barham; E C Chinje; G E Adams; A L Harris; I J Stratford
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

9.  Phase I/pharmacokinetic/biochemical study of the nitroimadazole hypoxic cell sensitiser SR2508 (etanidazole) in combination with cyclophosphamide.

Authors:  P J O'Dwyer; F P LaCreta; J Walczak; T Cox; S Litwin; J P Hoffman; M Zimny; R L Comis
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

10.  Synthesis and Biological Evaluation of Iodoglucoazomycin (I-GAZ), an Azomycin-Glucose Adduct with Putative Applications in Diagnostic Imaging and Radiotherapy of Hypoxic Tumors.

Authors:  Piyush Kumar; Hassan R H Elsaidi; Bohdarianna Zorniak; Evelyn Laurens; Jennifer Yang; Veena Bacchu; Monica Wang; Leonard I Wiebe
Journal:  ChemMedChem       Date:  2016-07-05       Impact factor: 3.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.